Evolent Health Inc. (NYSE:EVH) shares fell 3.9% on Thursday . The stock traded as low as $23.30 and last traded at $23.35, with a volume of 199,135 shares trading hands. The stock had previously closed at $24.29.

Several brokerages have weighed in on EVH. FBR & Co reiterated a “buy” rating on shares of Evolent Health in a research note on Saturday, May 14th. Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. Canaccord Genuity reiterated a “buy” rating and issued a $30.00 target price on shares of Evolent Health in a research note on Sunday, August 7th. Jefferies Group began coverage on Evolent Health in a research note on Tuesday, July 26th. They issued a “buy” rating and a $28.00 target price on the stock. Finally, Leerink Swann reiterated an “outperform” rating and issued a $20.00 target price on shares of Evolent Health in a research note on Sunday, July 17th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $22.50.

The firm’s market cap is $1.46 billion. The firm’s 50 day moving average price is $22.86 and its 200-day moving average price is $14.82.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.04. The business earned $56.50 million during the quarter, compared to analyst estimates of $51.96 million. The company’s revenue was up 443.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.95) EPS. Analysts anticipate that Evolent Health Inc. will post ($0.55) EPS for the current year.

An institutional investor recently raised its position in Evolent Health stock. Wells Fargo & Company MN boosted its stake in shares of Evolent Health Inc. (NYSE:EVH) by 22.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 808,909 shares of the company’s stock after buying an additional 145,685 shares during the period. Wells Fargo & Company MN owned approximately 1.37% of Evolent Health worth $9,796,000 as of its most recent SEC filing.

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.